Literature DB >> 3668258

Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA).

K F Karpinski1, S Hayward, H Tryphonas.   

Abstract

Several methods for analyzing ELISA data have been evaluated using optical density values derived by reacting serial two-fold dilutions of a rhesus monkey (Macaca mulatta) reference serum with dilutions of peroxidase-conjugated monospecific antisera to human IgG and IgM in the micro-ELISA 'sandwich' technique using microplates coated with appropriately diluted antisera to human IgG and IgM. Representation of optical density as a linear function of log serum dilution was shown to be inappropriate and potentially misleading. Weighted non-linear least squares analysis of a 4-parameter logit was demonstrated to be inappropriate because it required the specification of a somewhat arbitrary variance function and weight estimates varied substantially depending on the function used. Representation of optical density as a 4-parameter logistic function with estimation carried out on the log scale was shown to be the most appropriate procedure for determining the concentration of antigens or antibodies by the ELISA method.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3668258     DOI: 10.1016/0022-1759(87)90289-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  17 in total

1.  Use of coefficient of variation in assessing variability of quantitative assays.

Authors:  George F Reed; Freyja Lynn; Bruce D Meade
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

2.  The number of plaque-forming cells and its "normal range".

Authors:  M Jílek
Journal:  Folia Microbiol (Praha)       Date:  1989       Impact factor: 2.099

3.  Synthesis of site-specific methotrexate-IgG conjugates. Comparison of stability and antitumor activity with active-ester-based conjugates.

Authors:  J Kralovec; M Singh; M Mammen; A H Blair; T Ghose
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Kinetics of growth and leukotoxin production by Mannheimia haemolytica in continuous culture.

Authors:  James C du Preez; Eugéne van Rensburg; Stephanus G Kilian
Journal:  J Ind Microbiol Biotechnol       Date:  2008-02-19       Impact factor: 3.346

5.  Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.

Authors:  G Kanra; M Ceyhan; D Vandevoorde; H Bogaerts
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

6.  Preclinical pharmacology of cholera toxin.

Authors:  J M Reid; J W Benson; J Viallet; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay.

Authors:  B D Plikaytis; S H Turner; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

8.  Clinical trial with inactivated hepatitis A vaccine and recommendations for its use.

Authors:  A J Tilzey; S J Palmer; S Barrow; K R Perry; H Tyrrell; A Safary; J E Banatvala
Journal:  BMJ       Date:  1992-05-16

9.  Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.

Authors:  Giuseppe Ferrera; Mario Cuccia; Gabriele Mereu; Giancarlo Icardi; Gianni Bona; Susanna Esposito; Federico Marchetti; Marc Messier; Sherine Kuriyakose; Karin Hardt
Journal:  Hum Vaccin Immunother       Date:  2012-02-13       Impact factor: 3.452

10.  Xenogeneic monoclonal antibodies in the management of cancer: control of their in vivo immunogenicity and induction of specific unresponsiveness using an antibody-drug immunoconjugate.

Authors:  G B Sivolapenko; C Moreno; W Smith; J Corválan; M A Ritter; A A Epenetos
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.